While historically considered a late-stage event in PCa, somatic TP53 alterations are now also frequently recognized in localized and castration-sensitive metastatic stages, with increasing prevalence up to 50% in advanced and castration-resistant disease [6-8]. The gene discussed is TP53; the disease is posterior cortical atrophy.